Ovarian cancer in the elderly

Critical Reviews in Oncology/Hematology

Volumn 49, Issue 1, 2004, Pages 77-86

  Pignata, Sandro ^a   Vermorken, Jan B ^b  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b ANTWERP UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Elderly; Ovarian cancer

Indexed keywords

ANTIANDROGEN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; GESTAGEN; PACLITAXEL; PLATINUM; TAMOXIFEN;

BLOOD TOXICITY; CANCER EPIDEMIOLOGY; CANCER MORTALITY; CLINICAL TRIAL; EUROPE; HUMAN; INCIDENCE; OVARY CARCINOMA; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PROGNOSIS; QUALITY OF LIFE; REVIEW; SIDE EFFECT;

EID: 0347635280     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00100-8     Document Type: Review

References (96)

1. Olshansky S.J., Carnes B.A., Cassel C.K. The ageing of the human species. Sci. Am. 268:1993;46-52.
2. La Vecchia C., Lucchini F., Negri E., et al. Trends of cancer mortality in Europe 1955-89: breast and genital sites. Eur. J. Cancer. 28:1992;927-998.
3. Silverman M.A., Temple J.D. Cancer in the elderly patient. Unique aspects of presentation, management and screening. J. Fla. Med. Assoc. 79:1992;89-92.
4. Franceschi S., La Vecchia C. Cancer epidemiology in the elderly. Crit. Rev. Oncol. Hematol. 39:2001;219-226.
5. Hightower R.D., Nguyen H.N., Averette H.E., Hoskins W., Harrison T., Steren A. National survey of ovarian carcinoma IV: patterns of care and related survival for older patients. Cancer. 73:1994;377-383.
6. Riggs J.E. Rising ovarian cancer mortality in the elderly: a manifestation of differential survival. Gynecol. Oncol. 58:1995;64-67.
7. Ries L.A.G. Ovarian cancer. Survival and treatment differences by age. Cancer. 71:1993;254-529.
8. Ries L.A.G., Eisner M.P., Kosary C.L., Hankey B.F., Miller B.A., Clegg L., Edwards B.K. SEER cancer statistics review, 1973-1999. 2002;National Cancer Institute, Bethesda, MD. http://seer.cancer.gov/csr/1973_1999/.
9. Alberts D.S., Dahlberg S., Green S.J., et al. Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. Cancer. 71:1993;618-627.
10. Thigpen T., Brady M.F., Omura G.A., et al. Age as prognostic factor in ovarian carcinoma: the gynecologic oncology group experience. Cancer. 71:1993;606-614.
11. Edmonson J.H., Su J., Krook J.E. Treatment of ovarian cancer in elderly women. Cancer. 71:1993;615-617.
12. Gershenson D.M., Mitchell M.F., Atkinson N., et al. Age contrasts in patients with advanced epithelial ovarian cancer. Cancer. 7:1993;638-643.
13. Berchuck A., Kohler M., Boente M.P., et al. Growth regulation and trasformation of ovarian epithelium. Cancer. 71:1993;545-551.
14. Yancik R. Ovarian cancer. Age contrasts in incidence, histology, disease stage at diagnosis, and mortality. Cancer. 71:1993;517-523.
15. Grover S.A., Cook E.F., Adam J., et al. Delayed diagnosis of gynecologic tumors in elderly women: relation to national medical practice patterns. Am. J. Med. 86:1989;151-157.
16. Markman M., Lewis J.L., Saigo P., et al. Epithelial ovarian cancer in the elderly. Cancer. 71:1993;634-637.
17. Chiara S., Lionetto R., Vincenti M., et al. Advanced ovarian cancer in the elderly: results of consecutive trials with cisplatin-based chemotherapy. Crit. Rev. Oncol. Hematol. 37:2001;27-34.
18. Young R.C., Brady M.F., Walton L.A., Homesley H.D., Averette H.E., Long H.J. Localized ovarian cancer in the elderly. The gynecologic oncology group experience. Cancer. 71:1993;601-605.
19. Gronlud B., Hogdall C., Hansen H.H., Engelholm S.A. Performance status rather than age is the key prognostic factor in second-line treatment of elderly patients with epithelial ovarian carcinoma. Cancer. 94:2002;1961-1967.
20. Balducci L., Beghe C. The application of the principles of geriatrics to the management of the older persons with cancer. Crit. Rev. Oncol. Hematol. 35:2000;147-154.
21. Repetto L., Venturino A., Vercelli M., et al. Performance status and comorbidity in elderly cancer patients compared with young patients with neoplasia and elderly patients without neoplastic conditions. Cancer. 82:1998;760-851.
22. Balducci L., Extermann M. Cancer and aging. An evolving panorama. Hematol. Oncol. Clin. North Am. 14:2000;1-16.
23. Ceccaroni M., D'Agostino G., Ferrandina G., et al. Gynecological malignancies in elderly patients: is age 70 a limit to standard-dose chemotherapy? An Italian retrospective toxicity multicentric study. Gynecol. Oncol. 85:2002;445-450.
24. Monfardini S., Ferrucci L., Fratino L., et al. Validation of a multidimensional evaluation scale for use in elderly cancer patients. Cancer. 77:1996;395-401.
25. Repetto L., Fratino L., Audisio R.A., et al. Comprehensive geriatric assessment adds information to Eastern cooperative oncology group performance status in elderly cancer patients: an Italian group for geriatric oncology study. J. Clin. Oncol. 20:2002;494-502.
26. Bristow R.E., Tomacruz R.S., Armstrong D.K., Trimble E.L., Montz F.J. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J. Clin. Oncol. 20:2002;1248-1259.
27. Nordin A.J., Chinn D.J., Moloney I., Naik R., de Barros Lopes A., Monaghan J.M. Do elderly cancer patients care about cure? Attitudes to radical gynecologic oncology surgery in the elderly. Gynecol. Oncol. 81:2001;447-455.
28. Kirschner C.V., DeSerto T.M., Isaacs J.H., et al. Surgical treatment of the elderly patient with gynecologic cancer. Surg. Gynecol. Obstet. 170:1990;379-384.
29. Lawton F.G., Hacker N.F. Surgery for invasive gynaecologic cancer in the elderly female population. Obstet. Gynecol. 76:1990;287-289.
30. Levrant S.G., Fruchter R.G., Maiman M. Radical hysterectomy for cervical cancer: morbidity and survival in relation to weight and age. Gynecol. Oncol. 45:1992;317-322.
31. Karanikas ID, Liakakos TD, Koundorakis SS, Tzorakis SE, Dendrinos SS. Emergency operations in the elderly: management and outcome, Int Surg 1996;81:158-66.
32. Niettinen P., Pasanen P., Salomen P.A., Lahitinen J., Alahva E. The outcome of elderly patients after operation for acute abdomen. Ann. Chir. Gynecol. 85:1996;11-18.
33. Canver C., Nichols R.D., Cooler S.D., et al. Influence of age on long term survival after coronary artery by-pass grafting. Ann. Thorac. Surg. 62:1996;1123-1127.
34. Kennedy A.W., Flagg J.S., Webster K.D. Gynecologic cancer in the very elderly. Gynecol. Oncol. 32:1989;49-54.
35. Susini T., Scambia G., Margariti P.A., et al. Gynecologic oncologic surgery in the elderly: a retrospective analysis of 213 patients. Gynecol. Oncol. 75:1999;437-443.
36. Lichtinger M., Averette H., Penalver M., Sevin B.U. Major surgical procedures for gynaecologic malignancy in elderly women. South Med. J. 79:1986;1506-1510.
37. Giannice R., Susini T., Ferrandina G., et al. Systematic pelvic and aortic lymphadenectomy in elderly gynecologic oncologic patients. Cancer. 92:2001;2562-2568.
38. Di Re F., Baiocchi G., Fontanelli R., et al. Systematic pelvic and paraaortic lymphadenectomy for advanced ovarian cancer: prognostic significance of node metastases. Gynecol. Oncol. 62:1996;360-365.
39. Scarabelli C., Gallo A., Zarrelli A., Visentin C., Campagnutta E. Systematic pelvic and para-aortic lymphadenectomy durino cytoreductive surgery in advanced ovarian cancer. Potential benefit on survival. Gynecol. Oncol. 56:1995;328-337.
40. Onda T., Yoshikawa H., Yasugi T., et al. Patients with ovarian carcinoma up to stage III after lymphadenectomy have similar survival to stage I/II patients and superior survival to other stage III. Cancer. 83:1998;1555-1560.
41. Cloven N.G., Manetta A., Berman M.L., Kohler M.F., DiSaia P.J. Management of ovarian cancer in patients older than 80 years of age. Gynecol. Oncol. 73:1999;137-139.
42. Sundararajan V., Hershman D., Grann V.R., Jacobson J.S., Neugut A.I. Variations in the use of chemoterapy for elderly patients with advanced ovarian cancer: a population-based study. J. Clin. Oncol. 20:2002;173-178.
43. van Rijswijk R., Vermorken J.B. Drug therapy for gynaecological cancer in older women. Drugs Aging. 17:2000;13-32.
44. Balducci L., Corcoran M.B. Antineoplastic chemotherapy of the older cancer patient. Hematol. Oncol. Clin. North Am. 144:2000;193-212.
45. Balducci L., Beghe C. Pharmacology of chemotherapy in the older cancer patient. Cancer Control. 6:1999;466-470.
46. Markman M., Lewis J.L., Saigo P., et al. Epithelial ovarian cancer in the elderly. Cancer. 71:1993;634-637.
47. Lipschitz D.A. Age-related declines in hematopoietic reserve capacity. Semin. Oncol. 22:1995;3-5.
48. Trimble E.L., Cain D., Carter C.L., et al. Representation of the elderly in cancer clinical trials. Proc. Annu. Meet. Am. Soc. Clin. Oncol. 13:1994;527.
49. Monfardini S., Sorio R., Hoctin Boes G., Kaye S., Serraino D. Entry and evaluation of elderly patients in European organization for research and treatment of cancer (EORTC) new-drug-development studies. Cancer. 76:1995;333-338.
50. Pignata S., Monfardini S. Single agents should be administered in preference to combination chemotherapy for the treatment of patients over 70 years of age with advanced ovarian cancer. Eur. J. Cancer. 36:2000;817-820.
51. Randomized trial of single agent carboplatin against three-drug combination of CAP (cyclophosphamide, doxorubicin, and cisplatin) in women with ovarian cancer. Lancet. 352:1998;1571-1576.
52. Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial. Lancet. 360:2002;505-515.
53. Higgins R.V., Naumann R.W., Gardner J., Hall J.B. Is age a barrier to the aggressive treatment of ovarian cancer with paclitaxel and carboplatin. Gynecol. Oncol. 75:1999;464-467.
54. Repetto L., Ausili-Cefaro G., Gallo C., Rossi A., Manzione L. Quality of life in elderly cancer patients. Ann. Oncol. 12:(Suppl. 3):2001;S49-S52.
55. Balducci L., Stanta G. Cancer and frailty: a coming epidemic. Hematol. Oncol. Clin. North Am. 14:2000;235-250.
56. Clarke-Pearson D.L., Van Le L., Iveson T., et al. Oral topotecan as single-agent second-line chemotherapy in patients with advanced ovarian cancer. J. Clin. Oncol. 19:2001;3967-3975.
57. Gordon A.N., Fleagle J.T., Guthrie D., Parkin D.E., Gore M.E., Lacave A.J. Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan. J. Clin. Oncol. 19:2001;3312-3322.
58. Safra T., Groshen S., Jeffers S., et al. Treatment of patients with ovarian carcinoma with pegylated liposomal doxorubicin. Analysis of toxicities and predictors of outcome. Cancer. 91:2001;90-100.
59. Pignata S., Variale E., Casella G., et al. A phase I study of gemcitabine and epirubicin for the treatment of platinum-resistant or refractory advanced ovarian cancer. Ann. Oncol. 11:2000;613-616.
60. Baietta E., Zilembo N., Dowsett M., Guillevin L., Di Leo A., Celio L., Martinetti A., Marchiano A., Pozzi P., Stani S., Bichisao E. Phase II study of vinorelbine in patients with pre-treated advanced ovarian cancer: activity in platinum-resistant disease. J. Clin. Oncol. 14:1996;2541-2546.
61. Effects of vinorelbine on quality of life and survival of elderly patients with advanced non-small cell lung cancer, J Natl Cancer Inst 1999;91:66-72.
62. Gridelli C., Cigolari S., Gallo C., et al. Activity and toxicity of gemicitabine and gemicitabine+vinorelbine in advanced non-small-cell lung cancer elderly patients: phase II data from the multicenter Italian lung cancer in the elderly study (MILES) randomized trial. Lung Cancer. 31:2001;277-284.
63. de Wit R., van der Burg M.E.L., Gaast A.V.D., Logmans A., Stoter G., Verweij J. Phase II study of prolonged oral etoposide in patients with ovarian cancer refractory or relapsing within 12 months after platinum-containing chemotherapy. Ann. Oncol. 5:1994;656-657.
64. Delva R., Mege M., Gamelin E., et al. Maintien de l'intensitè de dose d'une chimiotherapie associant carboplatine, cyclophosphamide et etoposide chez la femme de plus de 70 ans atteinte d'un cancer de l'ovaire. Bull. Cancer. 83:1996;63-69.
65. van der Vange N., Greggi S., Burger C.W., et al. Experience with hormonal therapy in advanced ovarian cancer. Acta Oncol. 34:1995;813-820.
66. Ahlgren J.D., Ellison N.M., Godlieb R.J., et al. Hormonal palliation of chemotherapy resistant ovarian cancer: three consecutive phase II trials of the mid-Atlantic oncology program. J. Clin. Oncol. 11:1993;1957-1968.
67. van der Velden J., Gitsh G., Wain G.V., et al. Tamoxifen in patients with advanced epithelial ovarian cancer. Int. J. Gynecol. Cancer. 5:1995;301-305.
68. Veenhof C.H., van der Burg M.E., Nooy M., et al. Phase II study of high-dose megestrol acetate in patients with advanced ovarian cancer. Eur. J. Cancer. 30:1994;697-698.
69. Tumolo S., Rao B.R., van der Burg M.E., et al. Phase II trial of flutamide in advanced ovarian cancer: an EORTC gynecological cancer cooperative group study. Eur. J. Cancer. 30:1994;911-914.
70. Cornelison T.L., Reed E. Dose intensity of high-dose carboplatin in refractory ovarian carcinoma relative to age. Cancer. 71:1993;650-655.
71. Wright J.G., Boddy A.V., Highley M., Fenwick K., McGill A., Calvert A.H. Estimation of glomerular filtration rate in cancer patients. Br. J. Cancer. 84:2001;452-459.
72. Marx G.M., Steer C.B., Galani E., et al. Evaluation of the Cockroft Gault, Jeliffe and Wright formulae in estimating renal function in elderly patients. Proc. Am. Soc. Clin. Oncol. 20:2002;A1486.
73. Trimble E.L., Adams J.D., Vena D., et al. Paclitaxel for platinum-refracyory ovarian cancer: results from the first 1000 patients registered to National Cancer Institute Treatment Referral Center 9103. J. Clin. Oncol. 11:1993;2405-2410.
74. Bicher A., Sarosy G., Kohn E., et al. Age does not influence taxol dose intensity in recurrent carcinoma of the ovary. Cancer. 71:1993;594-600.
75. Fennelly D., Aghajanian C., Shapiro F., et al. Phase I and pharmacologic study of paclitaxel administered weekly in patients with relapsed ovarian cancer. J. Clin. Oncol. 15:1997;187-192.
76. Andersson H., Boman K., Ridderheim M., et al. An updated analysis of a randomized study of single agent paclitaxel given weekly vs. every 3 weeks to patients with ovarian cancer treated with prior platinum therapy. Proc. Am. Soc. Clin. Oncol. 19:2000;A1505.
77. Newcomb P.A., Carbone P.P. Cancer treatment and age: patient perspectives. J. Natl. Cancer Inst. 85:1993;1580-1584.
78. McKenna R.J. Clinical aspects of cancer in the elderly: treatment decisions, treatment choices, and follow up. Cancer. 74:1994;2107-2117.
79. Roila F., Tonato M., Basurto C., et al. Anti-emetic activity of high-dose of metoclopramide combined with methylprednisolone versus metoclopramide alone in cisplatin-treated cancer patients. J. Clin. Oncol. 5:1987;141-149.
80. Gerritsen van der Hoop R., van der Burg M.E.L., ten Bokkel Hinink W.W., et al. Incidence of neuropathy in 395 patients with ovarian cancer treated with or without cisplatin. Cancer. 66:1990;1697-1702.
81. Tuxen M.K., Hansen S.W. Complications of treatment: neurotoxicity secondary to antineoplastic drugs. Cancer Treat. Rev. 20:1994;191-214.
82. Guidozzi F. Living with ovarian cancer. Gynecol. Oncol. 50:1993;202-207.
83. Gomez H., Mas L., Casanova L., et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte- macrophage colony-stimulating factor: identification of two subgroups with different hematologic toxicity. J. Clin. Oncol. 16:1998;2352-2358.
84. Zinzani P.G., Storti S., Zaccaria A., et al. Elderly aggressive non-Hodgkin's lymphoma: first line VNCOP-B regimen: experience on 350 patients. Blood. 94:1999;33-38.
85. Seidenfeld J., Piper M., Flamm C., et al. Epoietin treatment of anemia associated with cancer therapy: a systematic review and meta-analysis of controlled clinical trials. J. Natl. Cancer Inst. 93:2001;1204-1214.
86. Aapro M.S., Cella D., Zagari M. Age, anemia, and fatigue. Semin. Oncol. 29:(Suppl. 8):2002;55-59.
87. Kurz C., Marth C., Windbichler G., et al. Erythropoietin treatment under polychemotherapy in patients with gynecologic malignancies: a prospective, randomized, double-blind placebo-controlled multicenter study. Gynecol. Oncol. 65:1997;461-466.
88. Heddens D., Alberts D., Hannigan E., et al. Prediction of the need for red cell transfusion in newly diagnosed ovarian cancer patients undergoing platinum-based treatment. Gynecol. Oncol. 86:2002;239-243.
89. Demetri G.D., Kris M., Wade J., et al. Quality-of-life benefit in chemotherapy patients treated with epoetin alfa is independent of disease response or tumor type: results from a prospective community oncology study. J. Clin. Oncol. 16:1998;3412-3425.
90. Cella D. The functional assessment of cancer therapy-anemia (FACT-An) scale: a new tool for the assessment of outcomes in cancer anemia and fatigue. Semin. Hematol. 34:1997;13-29.
91. Cleeland C.S., Demetri G.D., Glaspy J., et al. Identifyng haemoglobin levels for optimal quality of life. Results of an incremental analysis. Proc. Am. Soc. Clin. Oncol. 16:1999;A2215.
92. Kemp G., Rose P., Lurain J., et al. Amifostine pretreatment for protection against cyclophosphamide-induced and cisplatin-induced toxicities: results of a randomized control trial in patients with advanced ovarian cancer. J. Clin. Oncol. 14:1996;2101-2112.
93. Gelmon K., Eisenhouer E., Bryce C., et al. Randomized phase II study of high-dose paclitaxel with or without amifostine in patients with metastatic breast cancer. J. Clin. Oncol. 17:1999;3038-3047.
94. Budd G.T., Ganapathi R., Adelstein D.J., et al. Randomized trial of carboplatin plus amifostine versus carboplatin alone in patients with advanced solid tumors. Cancer. 80:1997;1134-1140.
95. Genvresse I., Lange C., Schanz J., et al. Tolerability of the cytoprotective agent amifostine in elderly patients receiving chemotherapy: a comparative study. Anticancer Drugs. 12:2001;345-349.
96. Spath-Schwalbe E., Lange C., Genvresse I., et al. Influence of amifostine on toxicity of CHOP in elderly patients with aggressive non-Hodgkin's lymphoma. A phase II study. Anticancer Drugs. 13:2002;395-403.